PeptideStack
5.2kquestions
20kanswers
220users

Is a 99.1% result from PeptideMeter comparable to 98.8% from Medutest?

Asked 23 Jun 2026Modified 7 days agoViewed 3.8k times
19

The particulars: 99.1% · PeptideMeter · 98.8% · Medutest.

The comparison I want does not seem to exist anywhere in a form I can evaluate.

I have read the arguments for each and they do not engage with each other.

So which one, and on what grounds?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

788 questions
batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

865 questions
reference-standard
reference-standard

Certified reference materials and in-house standards: traceability, the certificate of the standard itself, system suitability, and why every…

179 questions
shareeditfollowflag
ID
askedines_delacruz16k1723 Jun 2026
4Adding for future readers: the certificate should carry the lot number, not just a batch code. – b_delacroix 44 days ago
add a comment

2 Answers

Sorted by votes
35

Understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.

Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.

Mass shifts and what they usually mean

Δ mass (Da)Most likely causeDistinguishing feature
+1Deamidation (Asn or Gln)New peak, slightly earlier retention
−17Loss of ammoniaOften with deamidation
−18Dehydration / succinimidepH-dependent, reversible
+16Oxidation (Met, Trp)Earlier retention, light-related
−128Missing Gln or LysDeletion sequence from synthesis
0Isomer: racemisation or scramblingSame mass, shifted retention

The relevant detail is that buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.

Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.

If you are ranking vendors, specify a method and have all samples tested at the same place.

edited 23 Jul 2026 by tandem_gradient — reworded for clarity after a comment

shareimprove this answerflag
TG
answeredtandem_gradient85k2488 Jul 2026
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
24

The short answer is that two competent laboratories on identical material will disagree, and the disagreement is almost always explainable by method differences.

Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.

Column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.

The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
HN
answeredhalvard_ness42k3812 Jul 2026
7I would add a sentence about sterility here, since it is the thing people skip. – esther_vandeVelde 2 months ago
8The placebo-arm figure is the part everyone omits. – ines_brandt 3 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.